Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00793338|
Recruitment Status : Unknown
Verified November 2008 by University of New Mexico.
Recruitment status was: Not yet recruiting
First Posted : November 19, 2008
Last Update Posted : November 19, 2008
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure||Drug: Sildenafil||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||November 2010|
|Estimated Study Completion Date :||February 2011|
All patients will receive open-label treatment with sildenafil.
Sildenafil 20mg three times a day for 3 months.
- Change in 6-minute walk distance [ Time Frame: 24 hours and 3 months ]
- Changes in peak oxygen consumption (measured by cardiopulmonary exercise testing) [ Time Frame: 24 hours and 3 months ]
- Change in the level of neurohormones (b-type natriuretic peptide, catecholamines, ET-1), [ Time Frame: 24 hours and 3 months ]
- Change in quality of life [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793338
|Contact: Joe R Anderson, PharmDemail@example.com|
|United States, New Mexico|
|Clinical Translational Science Center||Recruiting|
|Albuquerque, New Mexico, United States, 87131|
|Principal Investigator: Joe R Anderson, PharmD|
|Principal Investigator:||Joe R Anderson, PharmD||University of New Mexico College of Pharmacy|